Kateryna Pivtorak

[Thomas Berg @ThomasBerg24]

When biology pushes back
HBsAg suppression works but #HDV biology is more complex than expected. ALT flares with siRNA monotherapy suggest that cure may require targeting HBV/HDV ecosystem, not just one viral dependency
DOI: 10.1016/j.jhep.2026.06.040 @JHepatology #LiverTwitter

[Javier Crespo @DrJavierCrespo]

Statins may be more than cardiovascular drugs in MASLD. Our review explores a coherent liver-specific framework linking the mevalonate pathway to inflammation, fibrosis, carcinogenesis and portal hemodynamics.
@sepdigestiva @AEEHLiver @IDIVALdecilla
https://t.co/a3Y0090uf6

[癒される動物 @cutest_animal1]

休日の移動方法

[Scott Isaacs @scottisaacsmd]

Fatty pancreas disorder is now defined as a distinct, organ-specific pathological state of excessive intrapancreatic fat that raises the risk of pancreatitis, pancreatic cancer and multiple forms of diabetes, best diagnosed with MRI.
https://t.co/B6p6n5rt5s

[Scott Isaacs @scottisaacsmd]

MASH is a systemic immunometabolic network disorder. New commentary highlights how GLP‑1–based therapies modulate the cardio‑hepato‑renal axis reprogramming disease biology.
https://t.co/2fhf8i8qWt

[Bilginiz Olsun @bilginzolsun]

Bu ses; 432 Hertz

Serotonin ve endorfin gibi mutluluk hormonlarının doğal yollarla salgılanmasına yardımcı olur, kan basıncını ve kalp ritmini düzenler.

[HEPATOLOGY Journal @HEP_Journal]

Review Article

MASH clinical trials and drugs pipeline: An impending tsunami

Noureddin
#LiverX
https://t.co/SUQfNovR66

[Madrigal Pharmaceuticals @MadrigalPharma]

We’re gearing up for @ADA_DiabetesPro Scientific Sessions where we’ll have the opportunity to engage in important conversations around the growing intersection of diabetes and MASH – and what it means for the future of metabolic health. Visit our team at Booth 1933. We hope to see you there! #ADA2026

[EASLnews @EASLnews]

🏛️ A historic moment for liver health.

Yesterday at the 79th World Health Assembly, Member States adopted the resolution "Steatotic liver disease: a missing piece in the global noncommunicable disease response" — the first time liver disease has ever been formally recognised within the global NCD agenda.

This is not a symbolic gesture. It is a mandate.

For too long, steatotic liver disease — affecting an estimated 1.5 billion people worldwide — has been absent from national health plans, NCD financing frameworks, and government accountability mechanisms. That changes now.

With this resolution, WHO Member States are called upon to: ✅ Integrate liver health into national NCD strategies ✅ Include liver health indicators in NCD monitoring frameworks ✅ Align health financing with integrated, prevention-centred care

As Professor Debbie Shawcross, EASL Secretary General, said at our WHA79 side event yesterday: "The NCD community has fought for decades to put prevention at the centre of health systems. Liver disease has been a missing piece. With this resolution, we have a mandate. Now we need governments to make it count."

The evidence is overwhelming. The EASL–Lancet Commission 2.0 estimates 780 preventable deaths per day and €55 billion in annual economic costs from liver disease in Europe alone.

The vote has been cast. Now the real work begins — and EASL will be there every step of the way.

👉 Read our full press release: https://t.co/9KvCsmpJMV

@DebbieShawcros1

[Madrigal Pharmaceuticals @MadrigalPharma]

Next week, we will be onsite at ISPOR 2026 hosted by @ISPORorg. Our Vice President, Medical Affairs & Health Economics, John O’Donnell, will speak on a panel about the real-world challenges of demonstrating HEOR’s impact and how the field can strengthen its visibility with decision-makers. Learn more: https://t.co/PUV1lsg7T8

#ISPORAnnual

[EASLnews @EASLnews]

Join the MICROB-PREDICT Consensus Conference "Microbiome-based mechanisms and biomarkers for improved patient stratification & therapeutic response prediction in decompensated cirrhosis and ACLF" taking place during #EASLCongress!

Discover the agenda: https://t.co/t7NfnZFWYp

[American Gastroenterological Association (AGA) @AmerGastroAssn]

IBD innovation from #DDW2026 — straight from the experts 👇
@drmikedolinger @ibdgijami @AdamFayeMD & Dr. Smyth break down real‑time monitoring, digital health & smarter care for underrepresented populations on Wednesday, May 13, noon EDT.

Register free➡️ https://t.co/7SkOJaVkAk

[Kateryna Pivtorak @Kateryna27372]

#LiverTwitter, exciting news! 🎉 My abstract has been accepted for #EASLCongress 2026 in Barcelona 🇪🇸 , from 27-30 May. I hope to see you there – secure your spot now and let's revolutionise liver science together! 💡👩‍🔬 https://t.co/M3CEVcLDu5 @EASLNews

[Tauseef Ali MD, FACG AGAF FACP @ibdtweets]

🚨 Fatigue in IBD: More Than Just Feeling Tired

🔹 Fatigue 101
Persistent, not relieved by rest
Multifactorial: inflammation, sleep issues, anemia, psychological health, gut-brain axis
Impacts quality of life, work, adherence, and mental health

[Frontline Gastro @FrontGastro_BMJ]

🩸@FrontGastro_BMJ:

Patients with IBD have a 57% increased risk of venous thromboembolism (VTE) within 30 days post-discharge (OR 1.57).

🛌 Risk after non-surgical admissions even higher (OR 1.70).

💉Should extended thromboprophylaxis be routine for our IBD patients?

👉 https://t.co/TOZBEMT57m

[Healio Gastroenterology @HealioGastro]

❗ Data from the ESSENCE trial led the #FDA to approve #Wegovy for certain adults with noncirrhotic #MASH.

✍️ @NoureddinMD of @MethodistHosp said the approval is a “welcome step that broadens options” for such patients.
https://t.co/noQm7uaEma

[Rohit Loomba @DrLoomba]

Delighted to report our new paper on DGAT-2 silencing in MASH- Antisense oligonucleotide DGAT-2 inhibitor, ION224, for MASH (ION224-CS2): results of a RCT, phase 2b trial - The Lancet https://t.co/fN3CDePkLl @AlkhouriNaim @MASLDResearch @CALonghurst